- Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma
- Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences
- Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars
- Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results
- Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease
- Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo
- Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data
- Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy
- Arrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences
More ▼
Key statistics
On Friday, Arrowhead Pharmaceuticals Inc (ARWR:NSQ) closed at 24.44, 18.24% above the 52 week low of 20.67 set on Dec 01, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 25.03 |
---|---|
High | 25.24 |
Low | 24.12 |
Bid | 21.00 |
Offer | 32.17 |
Previous close | 24.44 |
Average volume | 890.02k |
---|---|
Shares outstanding | 123.90m |
Free float | 118.33m |
P/E (TTM) | -- |
Market cap | 3.03bn USD |
EPS (TTM) | -2.77 USD |
Data delayed at least 15 minutes, as of May 03 2024 21:00 BST.
More ▼